1 Introduction Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related death [1, 2]. In 2020, more than 1.9 million new cases and approximately 930,000 CRC-related deaths were estimated globally, and this burden is projected to increase to 3.2 million new cases and 1.6 million deaths annually by 2040 [2].
Marc Bardou
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Marc
Contact Marc, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Tyrosine kinase inhibitors in Kosaki/Penttinen syndromes: new reports, follow-up of treated individuals and literature review
|
By Celine Jost, Alessandro Mussa, Jean-Emmanuel Kurtz, Ann Nordgren, Silvia Kalantari, Diana Carli, Andrea Gazzin, Claudio Isella, Enzo Medico, Thirona Naicker, Antoinette V. Chateau, Jean-Baptiste Demoulin, Nikolas Herold, Tara L. Wenger, Helena Iznardo, Eulalia Baselga, Jose Mascaro, Cecilie Bredrup, Titas Gladkauskas, Cecilie F. Rustad, Dinel Pond, Élise Schaefer, Maxime Luu, Marc Bardou, Laurence Faivre, Ashmika Gokhul, Anna Cassisa, Daniela Cantarella, Yordi-Michaël Bouhatous, Liubinka Mirakovska, Agnès Maurer, Théo Gaumet, Olav Aga Kildal, Ingrid Voktor Svinvik
|
Nature
Verified
Abstract Heterozygous activating variants in platelet-derived growth factor receptor beta (PDGFRβ) are associated with ultra-rare and clinically heterogeneous conditions, including KOGS (Kosaki Overgrowth Syndrome), PS (Penttinen Syndrome) and related conditons. Tyrosine kinase inhibitors (TKIs), which are widely used in hematological and oncological diseases, are now being explored as potential treatments for these conditions.
Risk of cervical cancer and high-grade lesions in vulnerable women a systematic review and meta-analysis - Nature Communications
Abstract Cervical cancer is largely preventable, yet causes around 300,000 deaths annually, disproportionately affecting vulnerable women. In here, we aim to estimate the risk of high-grade cervical lesions and cervical cancer among vulnerable populations in high- and upper-middle-income countries. We conduct a systematic review and meta-analysis of studies published up to February 2024 (from 2004 for HIV) across four databases. Risk of bias is assessed using the Newcastle–Ottawa Scale.
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Marc
Contact Marc, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack